Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove

Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), an important cause of treatment failure. The most widely used biologic across immune-mediated diseases is adalimumab, a tumor necrosis factor inhibitor. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsakok, Teresa, Saklatvala, Jake, Rispens, Theo, Loeff, Floris C., de Vries, Annick, Allen, Michael H., Barbosa, Ines A., Baudry, David, Dasandi, Tejus, Duckworth, Michael, Meynell, Freya, Russell, Alice, Chapman, Anna, McBride, Sandy, McKenna, Kevin, Perera, Gayathri, Ramsay, Helen, Ramesh, Raakhee, Sands, Kathleen, Shipman, Alexa, Burden, A. David, Griffiths, Christopher E.M., Reynolds, Nick J., Warren, Richard B., Mahil, Satveer, Barker, Jonathan, Dand, Nick, Smith, Catherine, Simpson, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977494/
https://www.ncbi.nlm.nih.gov/pubmed/36810251
http://dx.doi.org/10.1172/jci.insight.156643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977494/
https://www.ncbi.nlm.nih.gov/pubmed/36810251
http://dx.doi.org/10.1172/jci.insight.156643

Ejemplares similares